4DX — 4DMedical Income Statement
0.000.00%
- AU$819.35m
- AU$816.78m
- AU$5.85m
- 40
- 13
- 77
- 39
Annual income statement for 4DMedical, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.217 | 1.05 | 0.719 | 3.75 | 5.85 |
Cost of Revenue | |||||
Gross Profit | 0.125 | 0.281 | 0.684 | 3.52 | 5.39 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 19 | 25.5 | 32.2 | 40.7 | 36.1 |
Operating Profit | -18.7 | -24.5 | -31.5 | -36.9 | -30.2 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -21.4 | -24.5 | -31.1 | -35.9 | -30.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -21.4 | -24.6 | -31.5 | -36 | -30.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -21.4 | -24.6 | -31.5 | -36 | -30.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -21.4 | -24.6 | -31.5 | -36 | -30.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.082 | -0.084 | -0.105 | -0.093 | -0.138 |